ArticleProceedings of the National Academy of Sciences of the United States of America2026
In situ NMR and integrative proteomics reveal the interaction signature of serum α-synuclein.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- In situ NMR and integrative proteomics reveal the interaction signature of serum α-synuclein.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Alpha-synuclein (αS) plays a central role in several neurodegenerative diseases. Although predominantly neuronal, αS is also present in peripheral fluids such as serum and cerebrospinal fluid (CSF), where it may contribute to disease propagation. However, its extracellular interactions remain poorly understood. By combining in situ NMR spectroscopy and bottom-up MS proteomics, we reveal that monomeric αS exhibits distinct interactomes in serum versus CSF. Both N- and C-terminal αS regions bind to serum components, while in CSF, αS remains largely unbound. The N- and C-terminal interactions are mechanistically diverse: C-terminal binding is electrostatic, whereas N-terminal interactions persist under high ionic strength, implicating hydrophobic interactions. Deletion of the first ten N-terminal residues, which include several hydrophobic side chains, abolishes these interactions, highlighting their functional importance. Proteomic profiling and NMR validation identify key αS serum partners, including albumin, γ-globulins, and lipoproteins, which, together, are sufficient to recapitulate the serum αS interactome and elicit redundant interactions with the αS N-terminal region. Despite such redundancy, αS methionine oxidation selectively disrupts N-terminal binding, suggesting a redox-sensitive mechanism regulating the αS extracellular interactome. Notably, C-terminal interactions are preserved when the N-terminal binding is detuned, indicating that the N- and C-termini elicit independent interactions with the extracellular matrix, a marked difference from the intracellular milieu. These findings uncover dynamic and fluid-specific αS interaction signatures, offering new molecular insights into its peripheral roles and identifying potential new epitopes as synucleinopathy biomarkers. These results are also relevant for other amyloidogenic intrinsically disordered proteins (IDPs), for which αS serves as a prototype.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.